Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
ARDX Stock Chart & Stats
$5.93
-$0.17(-3.14%)
At close: 4:00 PM EST
$5.93
-$0.17(-3.14%)
Day’s Range― - ―
52-Week Range$3.21 - $6.78
Previous CloseN/A
Volume1.36M
Average Volume (3M)3.84M
Market Cap
$1.39B
Enterprise Value$1.30B
Total Cash (Recent Filing)$242.71M
Total Debt (Recent Filing)$207.61M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Mar 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding242,974,300
10 Day Avg. Volume2,942,891
30 Day Avg. Volume3,838,311
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)6.88
Price to Sales (P/S)3.57
P/FCF Ratio-26.03
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue3.26
Enterprise Value/Gross Profit3.67
Enterprise Value/Ebitda-45.68
Forecast
1Y Price Target
$11.50Price Target Upside93.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$400.90M
Bulls Say, Bears Say
Bulls Say
Market PositioningIbsrela remains a primary source of topline and value growth for Ardelyx, supported by its continued commercial success with record quarters in revenue.
Product DifferentiationIBSRELA has shown significant growth in the treatment of IBS-C, with a reported 92% year-over-year increase, positioning it as a differentiated treatment option.
Revenue GrowthManagement has raised guidance for Ibsrela's revenue, indicating strong confidence in its continued performance.
Bears Say
Medicare Coverage LossXPHOZAH faces challenges due to the loss of Medicare Part D coverage, impacting its commercial environment and requiring adjustments.
Revenue DeclineThe Y/Y decline in Xphozah revenue was due to the loss of Part D coverage due to oral only phosphate drugs being included in the ESRD 'bundle' on Jan. 1.
Ardelyx News
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $3.21 and its highest was $6.78 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $1.39B.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Mar 11, 2026 which is in 103 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Oct 30, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.058 by $0.058.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is 0.02.
How many shares outstanding does Ardelyx have?
Ardelyx has 242,974,300 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of $0 in its last earnings report, beating expectations of -$0.058. Following the earnings report the stock price went up 20.958%.
Which hedge fund is a major shareholder of Ardelyx?
Currently, no hedge funds are holding shares in ARDX
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.50 (93.93% Upside)
$11.50 (93.93% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 58.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $912.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.57%
12-Months-Change
Fundamentals
Return on Equity
-36.18%
Trailing 12-Months
Asset Growth
32.16%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with gastrointestinal and renal diseases. The company operates primarily in the healthcare sector and is known for its research and development of novel treatments that target unmet medical needs. Ardelyx's core products include tenapanor, a drug designed to treat patients with irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in patients with chronic kidney disease.
ARDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Ardelyx's strong financial performance, driven by significant growth in IBSRELA and XPHOZAH revenue. The introduction of a new compound, ARDX-10531, marks a positive step in pipeline development. However, challenges remain, particularly in achieving XPHOZAH's long-term revenue goals amidst market disruptions.View all ARDX earnings summariesARDX Stock 12 Month Forecast
Average Price Target
$11.50
▲(93.93% Upside)
Technical Analysis
Vericel
―
Viridian Therapeutics
―
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Ownership Overview
3.33% Insiders
20.07% Mutual Funds
1.62% Other Institutional Investors
63.00% Public Companies and Individual Investors